Margaret W Leigh1,2, Thomas W Ferkol3, Stephanie D Davis4, Hye-Seung Lee5, Margaret Rosenfeld6, Sharon D Dell7,8, Scott D Sagel9, Carlos Milla10, Kenneth N Olivier11, Kelli M Sullivan2,12, Maimoona A Zariwala2,13, Jessica E Pittman3, Adam J Shapiro1, Johnny L Carson1,14, Jeffrey Krischer5, Milan J Hazucha12,14, Michael R Knowles2,12. 1. 1 Department of Pediatrics. 2. 2 Marsico Lung Institute. 3. 3 Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri. 4. 4 Department of Pediatrics, Riley Children's Hospital, Indiana University School of Medicine, Indianapolis, Indiana. 5. 5 Department of Pediatrics, University of South Florida, Tampa, Florida. 6. 6 Seattle Children's Hospital, Seattle, Washington. 7. 7 Department of Paediatrics, The Hospital for Sick Children, and. 8. 8 Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. 9. 9 Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado. 10. 10 Department of Pediatrics, Stanford University, Palo Alto, California; and. 11. 11 National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland. 12. 12 Department of Medicine. 13. 13 Department of Pathology and Laboratory Medicine, and. 14. 14 Center for Environmental Medicine, Asthma and Lung Biology, UNC School of Medicine, Chapel Hill, North Carolina.
Abstract
RATIONALE: Primary ciliary dyskinesia (PCD), a genetically heterogeneous, recessive disorder of motile cilia, is associated with distinct clinical features. Diagnostic tests, including ultrastructural analysis of cilia, nasal nitric oxide measurements, and molecular testing for mutations in PCD genes, have inherent limitations. OBJECTIVES: To define a statistically valid combination of systematically defined clinical features that strongly associates with PCD in children and adolescents. METHODS: Investigators at seven North American sites in the Genetic Disorders of Mucociliary Clearance Consortium prospectively and systematically assessed individuals (aged 0-18 yr) referred due to high suspicion for PCD. The investigators defined specific clinical questions for the clinical report form based on expert opinion. Diagnostic testing was performed using standardized protocols and included nasal nitric oxide measurement, ciliary biopsy for ultrastructural analysis of cilia, and molecular genetic testing for PCD-associated genes. Final diagnoses were assigned as "definite PCD" (hallmark ultrastructural defects and/or two mutations in a PCD-associated gene), "probable/possible PCD" (no ultrastructural defect or genetic diagnosis, but compatible clinical features and nasal nitric oxide level in PCD range), and "other diagnosis or undefined." Criteria were developed to define early childhood clinical features on the basis of responses to multiple specific queries. Each defined feature was tested by logistic regression. Sensitivity and specificity analyses were conducted to define the most robust set of clinical features associated with PCD. MEASUREMENTS AND MAIN RESULTS: From 534 participants 18 years of age and younger, 205 were identified as having "definite PCD" (including 164 with two mutations in a PCD-associated gene), 187 were categorized as "other diagnosis or undefined," and 142 were defined as having "probable/possible PCD." Participants with "definite PCD" were compared with the "other diagnosis or undefined" group. Four criteria-defined clinical features were statistically predictive of PCD: laterality defect; unexplained neonatal respiratory distress; early-onset, year-round nasal congestion; and early-onset, year-round wet cough (adjusted odds ratios of 7.7, 6.6, 3.4, and 3.1, respectively). The sensitivity and specificity based on the number of criteria-defined clinical features were four features, 0.21 and 0.99, respectively; three features, 0.50 and 0.96, respectively; and two features, 0.80 and 0.72, respectively. CONCLUSIONS: Systematically defined early clinical features could help identify children, including infants, likely to have PCD. Clinical trial registered with ClinicalTrials.gov (NCT00323167).
RATIONALE: Primary ciliary dyskinesia (PCD), a genetically heterogeneous, recessive disorder of motile cilia, is associated with distinct clinical features. Diagnostic tests, including ultrastructural analysis of cilia, nasal nitric oxide measurements, and molecular testing for mutations in PCD genes, have inherent limitations. OBJECTIVES: To define a statistically valid combination of systematically defined clinical features that strongly associates with PCD in children and adolescents. METHODS: Investigators at seven North American sites in the Genetic Disorders of Mucociliary Clearance Consortium prospectively and systematically assessed individuals (aged 0-18 yr) referred due to high suspicion for PCD. The investigators defined specific clinical questions for the clinical report form based on expert opinion. Diagnostic testing was performed using standardized protocols and included nasal nitric oxide measurement, ciliary biopsy for ultrastructural analysis of cilia, and molecular genetic testing for PCD-associated genes. Final diagnoses were assigned as "definite PCD" (hallmark ultrastructural defects and/or two mutations in a PCD-associated gene), "probable/possible PCD" (no ultrastructural defect or genetic diagnosis, but compatible clinical features and nasal nitric oxide level in PCD range), and "other diagnosis or undefined." Criteria were developed to define early childhood clinical features on the basis of responses to multiple specific queries. Each defined feature was tested by logistic regression. Sensitivity and specificity analyses were conducted to define the most robust set of clinical features associated with PCD. MEASUREMENTS AND MAIN RESULTS: From 534 participants 18 years of age and younger, 205 were identified as having "definite PCD" (including 164 with two mutations in a PCD-associated gene), 187 were categorized as "other diagnosis or undefined," and 142 were defined as having "probable/possible PCD." Participants with "definite PCD" were compared with the "other diagnosis or undefined" group. Four criteria-defined clinical features were statistically predictive of PCD: laterality defect; unexplained neonatal respiratory distress; early-onset, year-round nasal congestion; and early-onset, year-round wet cough (adjusted odds ratios of 7.7, 6.6, 3.4, and 3.1, respectively). The sensitivity and specificity based on the number of criteria-defined clinical features were four features, 0.21 and 0.99, respectively; three features, 0.50 and 0.96, respectively; and two features, 0.80 and 0.72, respectively. CONCLUSIONS: Systematically defined early clinical features could help identify children, including infants, likely to have PCD. Clinical trial registered with ClinicalTrials.gov (NCT00323167).
Authors: Stephanie D Davis; Thomas W Ferkol; Margaret Rosenfeld; Hye-Seung Lee; Sharon D Dell; Scott D Sagel; Carlos Milla; Maimoona A Zariwala; Jessica E Pittman; Adam J Shapiro; Johnny L Carson; Jeffrey P Krischer; Milan J Hazucha; Matthew L Cooper; Michael R Knowles; Margaret W Leigh Journal: Am J Respir Crit Care Med Date: 2015-02-01 Impact factor: 21.405
Authors: P G Noone; W D Bennett; J A Regnis; K L Zeman; J L Carson; M King; R C Boucher; M R Knowles Journal: Am J Respir Crit Care Med Date: 1999-07 Impact factor: 21.405
Authors: Michael R Knowles; Lawrence E Ostrowski; Margaret W Leigh; Patrick R Sears; Stephanie D Davis; Whitney E Wolf; Milan J Hazucha; Johnny L Carson; Kenneth N Olivier; Scott D Sagel; Margaret Rosenfeld; Thomas W Ferkol; Sharon D Dell; Carlos E Milla; Scott H Randell; Weining Yin; Aruna Sannuti; Hilda M Metjian; Peadar G Noone; Peter J Noone; Christina A Olson; Michael V Patrone; Hong Dang; Hye-Seung Lee; Toby W Hurd; Heon Yung Gee; Edgar A Otto; Jan Halbritter; Stefan Kohl; Martin Kircher; Jeffrey Krischer; Michael J Bamshad; Deborah A Nickerson; Friedhelm Hildebrandt; Jay Shendure; Maimoona A Zariwala Journal: Am J Respir Crit Care Med Date: 2014-03-15 Impact factor: 21.405
Authors: Adam J Shapiro; Stephanie D Davis; Thomas Ferkol; Sharon D Dell; Margaret Rosenfeld; Kenneth N Olivier; Scott D Sagel; Carlos Milla; Maimoona A Zariwala; Whitney Wolf; Johnny L Carson; Milan J Hazucha; Kimberlie Burns; Blair Robinson; Michael R Knowles; Margaret W Leigh Journal: Chest Date: 2014-11 Impact factor: 9.410
Authors: J F Papon; A Coste; F Roudot-Thoraval; M Boucherat; G Roger; A Tamalet; A M Vojtek; S Amselem; E Escudier Journal: Eur Respir J Date: 2009-10-19 Impact factor: 16.671
Authors: Marcus P Kennedy; Heymut Omran; Margaret W Leigh; Sharon Dell; Lucy Morgan; Paul L Molina; Blair V Robinson; Susan L Minnix; Heike Olbrich; Thomas Severin; Peter Ahrens; Lars Lange; Hilda N Morillas; Peadar G Noone; Maimoona A Zariwala; Michael R Knowles Journal: Circulation Date: 2007-05-21 Impact factor: 29.690
Authors: Lisa R Young; Bruce C Trapnell; Kenneth D Mandl; Daniel T Swarr; Jennifer A Wambach; Carol J Blaisdell Journal: Ann Am Thorac Soc Date: 2016-12
Authors: Weining Yin; Alessandra Livraghi-Butrico; Patrick R Sears; Troy D Rogers; Kimberlie A Burns; Barbara R Grubb; Lawrence E Ostrowski Journal: Am J Respir Cell Mol Biol Date: 2019-09 Impact factor: 6.914
Authors: Adam J Shapiro; Sharon D Dell; Benjamin Gaston; Michael O'Connor; Nadzeya Marozkina; Michele Manion; Milan J Hazucha; Margaret W Leigh Journal: Ann Am Thorac Soc Date: 2020-02
Authors: Jacelyn E Peabody; Ren-Jay Shei; Brent M Bermingham; Scott E Phillips; Brett Turner; Steven M Rowe; George M Solomon Journal: Am J Physiol Lung Cell Mol Physiol Date: 2018-03-01 Impact factor: 5.464
Authors: Adam J Shapiro; Maureen Josephson; Margaret Rosenfeld; Ozge Yilmaz; Stephanie D Davis; Deepika Polineni; Elena Guadagno; Margaret W Leigh; Valery Lavergne Journal: Ann Am Thorac Soc Date: 2017-07
Authors: Margaret W Leigh; Amjad Horani; BreAnna Kinghorn; Michael G O'Connor; Maimoona A Zariwala; Michael R Knowles Journal: Transl Sci Rare Dis Date: 2019-07-04
Authors: Adam J Shapiro; Stephanie D Davis; Deepika Polineni; Michele Manion; Margaret Rosenfeld; Sharon D Dell; Mark A Chilvers; Thomas W Ferkol; Maimoona A Zariwala; Scott D Sagel; Maureen Josephson; Lucy Morgan; Ozge Yilmaz; Kenneth N Olivier; Carlos Milla; Jessica E Pittman; M Leigh Anne Daniels; Marcus Herbert Jones; Ibrahim A Janahi; Stephanie M Ware; Sam J Daniel; Matthew L Cooper; Lawrence M Nogee; Billy Anton; Tori Eastvold; Lynn Ehrne; Elena Guadagno; Michael R Knowles; Margaret W Leigh; Valery Lavergne Journal: Am J Respir Crit Care Med Date: 2018-06-15 Impact factor: 21.405
Authors: Timothy J Vece; Scott D Sagel; Maimoona A Zariwala; Kelli M Sullivan; Kimberlie A Burns; Susan K Dutcher; Roman Yusupov; Margaret W Leigh; Michael R Knowles Journal: Pediatr Pulmonol Date: 2019-09-23